Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays

Qun Yan; Melissa J. Karau; Yash S. Raval; Robin Patel

doi:10.1128/AAC.00943-18

Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays

Qun Yan, Melissa J. Karau, Yash S. Raval, Robin Patel

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)- related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.

Original language	English (US)
Article number	e00943
Journal	Antimicrobial Agents and Chemotherapy
Volume	62
Issue number	10
DOIs	https://doi.org/10.1128/AAC.00943-18
State	Published - Oct 2018

Keywords

Biofilm
Gentamicin
Linezolid
Methicillin-resistant Staphylococcus aureus
Oritavancin
Rifampin

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00943-18

Cite this

Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays. / Yan, Qun; Karau, Melissa J.; Raval, Yash S. et al.
In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 10, e00943, 10.2018.

Research output: Contribution to journal › Article › peer-review

@article{81e97b3af6a143768c61968279806eb5,

title = "Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays",

abstract = "The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)- related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.",

keywords = "Biofilm, Gentamicin, Linezolid, Methicillin-resistant Staphylococcus aureus, Oritavancin, Rifampin",

author = "Qun Yan and Karau, {Melissa J.} and Raval, {Yash S.} and Robin Patel",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Microbiology.",

year = "2018",

month = oct,

doi = "10.1128/AAC.00943-18",

language = "English (US)",

volume = "62",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays

AU - Yan, Qun

AU - Karau, Melissa J.

AU - Raval, Yash S.

AU - Patel, Robin

PY - 2018/10

Y1 - 2018/10

N2 - The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)- related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.

AB - The antibiofilm activity of oritavancin in combination with rifampin, gentamicin, or linezolid was evaluated against 10 prosthetic joint infection (PJI)- related methicillin-resistant Staphylococcus aureus (MRSA) isolates by time-kill assays. Oritavancin combined with rifampin demonstrated statistically significant bacterial reductions compared with those of either antimicrobial alone for all 10 isolates (P ≤ 0.001), with synergy being observed for 80% of the isolates. Oritavancin and rifampin combination therapy may be an option for treating MRSA PJI.

KW - Biofilm

KW - Gentamicin

KW - Linezolid

KW - Methicillin-resistant Staphylococcus aureus

KW - Oritavancin

KW - Rifampin

UR - http://www.scopus.com/inward/record.url?scp=85053551173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053551173&partnerID=8YFLogxK

U2 - 10.1128/AAC.00943-18

DO - 10.1128/AAC.00943-18

M3 - Article

C2 - 30012765

AN - SCOPUS:85053551173

SN - 0066-4804

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 10

M1 - e00943

ER -

Evaluation of oritavancin combinations with rifampin, gentamicin, or linezolid against prosthetic joint infection-associated methicillin-resistant staphylococcus aureus biofilms by time-kill assays

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this